XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.3
Collaboration and license agreements (Tables)
 9 Months Ended
Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summary of allocation of transaction price
The following table summarizes the allocation of the total transaction price to the identified performance obligations under the arrangement, and the amount of the transaction price unsatisfied as of September 30, 2024 (in thousands):
Transaction
Price
Allocated		Transaction
Price
Unsatisfied
Performance obligations:  
Research and development targets$16,688 $13,823 
Option rights2,376 2,376 
Total$19,064 $16,199 
Schedule of revenue from collaboration agreements
Revenue from collaboration agreements for the three and nine months ended September 30, 2024 and 2023 in the condensed consolidated statements of operations and comprehensive loss was as follows (in thousands):
 Three Months Ended September 30,Nine Months Ended September 30,
 2024202320242023
Revenue from collaboration agreements:  
MKDG Agreement$2,368 $— $4,317 $— 
Merck Agreement1,684 — 3,431 — 
Betta Agreements2,896 — 2,896 — 
Roche Agreement414 8,223 2,865 8,736 
Biogen Agreement8,000 2,849 16,898 7,689 
Calico Agreement— — — 1,070 
Total revenue from collaboration agreements$15,362 $11,072 $30,407 $17,495 
Schedule of financial information related to collaboration and license agreements
Financial information related to the collaboration and license agreements consisted of the following in the Company’s condensed consolidated balance sheet as of September 30, 2024 (in thousands):
 Accounts
Receivable		Deferred Revenue,
Current		Deferred Revenue,
Net of Current		Deferred Revenue,
Total
Supplemental information:    
MKDG Agreement$1,572 $4,770 $9,652 $14,422 
Merck Agreement— 6,569 — 6,569 
Betta Agreements769 4,203 11,107 15,310 
Roche Agreement— 5,227 7,889 13,116 
Biogen Agreement8,000 — — — 
Total$10,341 $20,769 $28,648 $49,417 
Financial information related to the collaboration and license agreements consisted of the following in the Company’s condensed consolidated balance sheet as of December 31, 2023 (in thousands):
 Accounts
Receivable		Deferred Revenue,
Current		Deferred Revenue,
Net of Current		Deferred Revenue,
Total
Supplemental information:    
Merck Agreement$10,000 $8,000 $2,000 10,000 
Betta Agreement1,799 4,000 8,000 12,000 
Roche Agreement— 2,667 11,814 14,481 
Biogen Agreement— 804 — 804 
Total$11,799 $15,471 $21,814 $37,285 
Schedule of supplemental financial information related to collaboration and license agreements
Supplemental financial information related to the collaboration and license agreements for the three and nine months ended September 30, 2024 and 2023 are (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Revenue recognized that was included in the contract liability at the beginning of the period$4,994 $2,664 $9,996 $5,895